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Abstract
Background: Indigenous Australians diagnosed with cancer have poorer survival compared to non-Indigenous
Australians. We aim to: 1) identify differences by Indigenous status in out-of-pocket expenditure for the first three-
years post-diagnosis; 2) identify differences in the quantity and cost of healthcare services accessed; and 3) estimate
the number of additional services required if access was equal between Indigenous and non-Indigenous people
with cancer.
Methods: We used CancerCostMod, a model using linked administrative data. The base population was all persons
diagnosed with cancer in Queensland, Australia (01JUL2011 to 30JUN2012) (n = 25,553). Each individual record was
then linked to their Admitted Patient Data Collection, Emergency Data Information System, Medicare Benefits
Schedule (MBS), and Pharmaceutical Benefits Scheme (PBS) records (01JUL2011 to 30JUN2015). We then weighted
the population to be representative of the Australian population (approximately 123,900 Australians, 1.7%
Indigenous Australians). The patient co-payment charged for each MBS service and PBS prescription was summed
for each month from date of diagnosis to 36-months post-diagnosis. We then limited our model to MBS items to
identify the quantity and type of healthcare services accessed during the first three-years.
Results: On average Indigenous people with cancer had less than half the out-of-pocket expenditure for each 12-month
period (0–12months: mean $401 Indigenous vs $1074 non-Indigenous; 13–24months: mean $200 vs $484; and 25–36
months: mean $181 vs $441). A stepwise generalised linear model of out-of-pocket expenditure found that Indigenous
status was a significant predictor of out of pocket expenditure. We found that Indigenous people with cancer on average
accessed 236 services per person, however, this would increase to 309 services per person if Indigenous people had the
same rate of service use as non-Indigenous people.
Conclusions: Indigenous people with cancer had lower out-of-pocket expenditure, but also accessed fewer Medicare
services compared to their non-Indigenous counterparts. Indigenous people with cancer were less likely to access
specialist attendances, pathology tests, and diagnostic imaging through MBS, and more likely to access primary health
care, such as services provided by general practitioners.
Keywords: Cost, Rurality, Socioeconomic, Indigenous
* Correspondence: e.callander@griffith.edu.au
1School of Medicine, Griffith University, Gold Coast, Australia
2Australian Institute of Tropical Health and Medicine (AITHM), James Cook
University, Townsville, Australia
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Callander et al. International Journal for Equity in Health           (2019) 18:32 
https://doi.org/10.1186/s12939-019-0931-4
Background
Aboriginal and Torres Strait Islander people (hereafter
respectfully referred to as Indigenous Australians) have
poorer survival after a cancer diagnosis compared to
non-Indigenous Australians [1–4]. Between 2007 and
2014, five-year survival for Indigenous Australians was
50% compared to 65% for non-Indigenous Australians
[1]. Indigenous Australians living in remote areas have
much lower survival compared to those living in metro-
politan areas [3, 5]. A number of studies have identified
factors contributing to this survival inequality, including
Indigenous Australians having increased risk factors for
developing cancer [2], lower participation rates in
national screening programs [2] and being more likely to
be diagnosed with advanced disease [2, 4, 6].
Evidence also shows that there are differences in
access to and uptake of treatment between Indigenous
and non-Indigenous Australians [4, 7–9]. The reasons
for this difference in access to and uptake of treatment
are potentially complex and multifactorial, but include
difficulty in geographical accessibility of services, and
issues with the cultural and personal acceptability of ser-
vices, in addition to clinical decisions about which
options are offered to individuals [8, 9]. In order to de-
velop the best treatment pathway for an individual,
many clinical factors will be considered by the treating
specialist. Indigenous Australians are more likely to be
diagnosed with an increased stage of disease [4, 9], and
have an increased number of comorbidities [4, 7, 9],
which may alter the treatment options that are available
or offered. These are “supply side” issues influencing the
services that are accessed.
In addition to these supply side or clinical driven fac-
tors, there may be patient driven factors influencing
treatment decisions. These are “demand side” issues in-
fluencing the services that are accessed. Physical location
is an important consideration in the decision to access
care for people living outside of urban areas. In rural or
regional areas of Australia there are fewer oncology ser-
vices available locally [10], and as such patients may be
required to travel or relocate for treatment [11, 12].
Travel and accommodation for cancer patients comes at
a high out of pocket cost [11], and there are large non--
financial and other opportunity costs such as separ-
ation and isolation.
The overall cost of access to health care, through
travel, accommodation, opportunity costs and the
patient co-payment amounts often required to access
healthcare outside of public hospitals in Australia, will
influence demand for services. Previous research has
indicated that, internationally, between 28 and 43% of
cancer patients report financial distress or hardship as a
result of expenditure on their cancer treatment (called
“financial toxicity”) [13]. Such demand side access
considerations may also be particularly important for
Indigenous Australians, as a higher proportion of Indi-
genous Australians live in remote areas [14] and are
more likely to be socioeconomically disadvantaged [15]
and thus more likely to face higher transport costs for
accessing care alongside a lower ability to pay. Under-
standing how much is paid for healthcare by people with
cancer is an important part in understanding differences
in access to care, as high out of pocket cost will act to
reduce consumption of services.
Australia has a universal health care system and its
public health insurance program, Medicare, provides
free treatment at public hospitals, and free or subsidized
medical treatment for care outside public hospitals [16].
Outside of public hospitals, if there is a difference be-
tween the amount the provider of a service charges and
the rebate amount paid under Medicare, the patient is
charged a co-payment. The Medicare system is designed
to ensure that all people have access to the care they
need, and that there is equity in payment for services so
that the cost to the patient does not act as a barrier to
accessing care [17]. However, for out-of-hospital medical
services, the price set by service provider is unregulated,
thus the charge to the patient is dependent on what the
provider charges. The Pharmaceutical Benefits Scheme
(PBS) is a part of Australia’s universal health system and
seeks to provide affordable access to pharmaceuticals
for Australians. The PBS contains a list of approved
medications, which may be available at a subsidised
rate (patients paying up to a set co-payment charge
and the balance subsidised by the Australian govern-
ment) with a valid prescription [16].
Australia has several policies which further assist indi-
viduals and family groups access healthcare by reducing
the cost of individual services or the amount of overall
expenditure. Once an individual or family group reaches
a given level of out of pocket expenditure on
co-payments during the calendar year, the individual or
family group will have a higher proportion of their fees
subsidized for the remainder of the year under the
“Medicare Safety Net” scheme [16]. Furthermore, in
2010, the Closing the Gap (CTG) PBS Co-payment
Programme was initiated to reduce the co-payment
amounts for prescription medications to eligible In-
digenous people living with, or at risk of chronic
disease [18].1
Despite these policies to reduce costs to the patient
for healthcare and the associated decline in demand for
healthcare, 21% of people with cancer in Australia state
that they skipped care due to the cost [19]. Within
Australia, previous studies have quantified the out of
pocket expenditure for breast cancer, prostate cancer
and lymphedema patients, and patients living in rural
areas [11, 20–24]. However, to date, none have sought to
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quantify the expenditure on healthcare for Indigenous
people with cancer and none have sought to take into
account the differences in access to health services when
quantifying expenditure. Understanding the amount paid
for healthcare by Indigenous people with cancer is im-
portant to determine the effectiveness of the current
policies to minimise healthcare co-payments for Indi-
genous Australians, and also in ensuring that demand
for healthcare is not reduced by high out of pocket cost.
The aims of this study were to: 1) identify if there is a
difference in the long-term out of pocket healthcare ex-
penditure on healthcare services incurred by Indigenous
and non-Indigenous people with cancer; 2) identify
whether there is any difference in the quantity and cost
of individual services being accessed that may be con-
tributing to the differences in total expenditure; and 3)
estimate the number of additional health services that
would be required to be supplied if access for different
types of services was equal between Indigenous and
non-Indigenous people with cancer.
Methods
Study design and participants
This study used a model of cancer costs based upon a
whole of population linked dataset, CancerCostMod.
The data linkage [25] and the development of Cancer-
CostMod have been described in detail elsewhere [26].
Briefly, the base population of this dataset was a census
of all patients diagnosed with cancer in Queensland,
Australia, between 1 July 2011 and 30 June 2012, as re-
corded by the Queensland Cancer Registry (QCR) (N =
25,553). All cancer diagnoses in Australia, except for
non-melanoma skin cancer are required by law to be
recorded by the jurisdiction’s cancer registry. Each indi-
vidual’s record was then linked to their Queensland
Health Admitted Patient Data Collection (QHAPDC),
Emergency Department Information System (EDIS),
Medicare Benefits Schedule (MBS), and Pharmaceutical
Benefits Scheme (PBS) records from 1 July 2011 to 30
June 2015.
Socioeconomic status and rurality
We mapped the patient’s residential postcode at
diagnosis to the Index of Relative Socio-Economic
Disadvantage (IRSD) [27] and Australian Statistical
Geography Standard (ASGS) [28], which were both
developed by the Australian Bureau of Statistics’
(ABS). IRSD is a summary score of an area’s the
economic and social conditions. Areas are assigned a
score and then grouped into deciles ranked from
highest to lowest economic and social status, as such
it is a measure of relative disadvantage only. The
authors then collapsed IRSD into quintiles, where
Q1 was the most disadvantaged and Q5 was the
least disadvantaged. The ASGS categorises remote-
ness into: major cities, inner regional, outer regional,
remote, and very remote. The authors collapsed rur-
ality into three categories: ‘metropolitan’, ‘regional’,
and ‘remote’. Postcode was unknown for 151
records, and as such these were unable to be
mapped to IRSD or ASGS.
Indigenous identification
The original QCR dataset recorded whether people with
cancer identified as Indigenous Australian or not for
87% of records. We used multiple imputation to impute
the 13% of records with missing data for this variable, as
described previously [26].
Cost for total patient co-payment
The MBS and PBS datasets contained information on
the total amount charged for the service or prescription,
the Medicare rebate, and the patient co-payment. The
patient co-payment was summed for MBS and PBS from
the date of diagnosis for each month up to 36months to
give the expenditure for MBS and PBS separately. The
patient co-payment was assigned a value of ‘0’ if the
patient was alive, but had no recorded expenditure, and
a missing value if the patient had died.
Descriptive analyses were performed to identify the
relevant social and demographic characteristics of the
sample (both weighted and non-weighted where
appropriate), as well as the average annual patient
expenditure (MBS and PBS combined) for Indigenous
and non-Indigenous individuals for the first three
years following diagnosis.
A stepwise generalized linear model was conducted to
assess whether there was any difference in patient ex-
penditure (MBS and PBS combined) between Indigenous
and non-Indigenous patients, after accounting for differ-
ences in demographic and social characteristics. Age at
diagnosis, Indigenous identification (reference group =
non-Indigenous), sex (reference group =male), rurality
(regional; remote; reference group =metropolitan),
area-based deprivation quintile (reference group =Q1),
and broad cancer site groupings (18 categories: head and
neck; digestive organs; colorectal cancer; female genital
organs; breast cancer; prostate cancer; male genital or-
gans excluding prostate; urinary tract; eye, brain and
other parts of the central nervous system; mesothelioma,
Kaposi sarcoma and soft tissue; thyroid and other endo-
crine organs; other thoracic and respiratory organs;
bone; tracheal, bronchus and lung; other skin;
melanoma; blood and lymphatic system; and other or
ill-defined cancers) were included as co-variates in the
model. As with most cost data, patient expenditure was
skewed. As such, we utilised generalised linear regres-
sion modelling, and selected a negative binomial
Callander et al. International Journal for Equity in Health           (2019) 18:32 Page 3 of 11
distribution, with a log link function as the best repre-
sentation of the data. In order to account for censoring
due to death, with some patients living for the full
thirty-six months and others living for shorter amounts
of time, we also included the log of the number of
months the patient survived as an offset to the model. A
stepwise approach to this model was utilised to examine
whether being Indigenous remained a significant pre-
dictor of expenditure when rurality, and then area-based
deprivation were added to the model, as these are
known to be strongly associated with access and out of
pocket costs [11, 29].
Research suggests that a high proportion of Indigenous
Australians live in rural/remote areas within Australia,
as well as being more socio-economically disadvan-
taged than non-Indigenous Australians [3, 5]. To ac-
count for the possible collinearity of Indigenous
status, rurality and socio-economic disadvantage, the
analyses as explained above was first performed using
a multiple linear regression analysis to examine
collinearity. The output of this analysis revealed no
significant collinearity between variables, with all VIF
values < 5 and no tolerance values > 1.
Cost of MBS broad type of service (BTOS)
We then limited our dataset to MBS data only to further
examine the types of services covered by the Medicare
scheme that each patient was accessing. The MBS item
code of each occasion of service was assigned to a Medi-
care Broad Types of Service (BTOS), which is defined by
the Australian Department of Health. There are 18
overarching BTOS categories of Medicare item codes, as
outlined in Table 1 [30]. The authors mapped MBS item
codes from the MBS dataset to 16 BTOS categories (the
final two categories were non-MBS, and therefore,
not included in the mapping). Items falling into the
Obstetrics BTOS were excluded due to low numbers.
Initial descriptive analyses were performed to examine
the difference in both expenditure and frequency of use
for each BTOS, stratified by Indigenous and
Table 1 A brief example of the types of item codes in each BTOS category [42]
BTOS Category Examples of services included
Non-referred attendances – General Practitioner (GP)/
Vocationally registered GP (VRGP) (101)
Attendance by a GP or VRGP
Non-referred attendances – enhanced primary care
(102)
Health assessments; GP management plans, team care arrangements and multidisciplinary
care plans; case conferences; GP mental health treatment plans; domiciliary and residential
management reviews
Non-referred attendances – other (103) Professional attendance at consulting rooms, or nursing home, or hospital, to which no
other item applies; family group therapy, examination by a specialist in preparation for the
administration of anaesthetic
Practice nurse items (110) Services provided by a practice nurse or Aboriginal and Torres Strait Islander Health
Practitioner on behalf of a medical practitioner
Other allied health (150) Aboriginal and Torres Strait Islander services provided by an eligible Aboriginal health
worker or Aboriginal and Torres Strait Islander Health Practitioner, dental services, diabetes
education services, mental health services, physiotherapy services, etc
Specialist attendance (200) Attendances by a consultant physician practicing in his or her own specialty, and was not
limited to specialists practicing in haematology, medical oncology, radiation oncology, or
surgical oncology
Anaesthetics (400) Administration of anaesthetic for medical procedures
Pathology collection items (501) Initiation of a patient episode by collection of a specimen
Pathology tests (502) Included all pathology tests, such as simple basic pathology tests, chemical, haematology,
immunology, microbiology, tissue pathology, and cytology
Diagnostic imaging (600) Included all modalities (ie ultrasound, computed tomography, diagnostic radiography,
magnetic resonance imaging, nuclear medicine imaging), and for all purposes (ie general,
cardiac, vascular, injury, obstetric and gynaecological)
Operations (700) Surgical procedures for any speciality, including colorectal, ear nose and throat, general,
gynaecological, plastics and reconstructive, urological, vascular, etc
Assistance at operations (800) 11 item codes for which assistance was required during an operation
Optometry (900) Initial consultations, subsequent consultations, appointments for contact lenses etc
Radiotherapy and therapeutic nuclear medicine (1000) Included item codes for radiation oncology such as superficial, megavoltage,
brachytherapy, and computerised planning; as well as therapeutic nuclear medicine such
as administration of a radioisotope, or iodine etc.
Other MBS services (1100) Other diagnostic and therapeutic procedures not listed elsewhere
A full list of MBS item codes mapped to the BTOS are available from the MBS website (www.mbsonline.gov.au)
Callander et al. International Journal for Equity in Health           (2019) 18:32 Page 4 of 11
non-Indigenous people with cancer. Generalised linear
models using a log link function and a negative binomial
distribution with an overset for survival were con-
structed, with the average expenditure or frequency of
use for each BTOS category used as the outcome vari-
able. All models were adjusted for age at diagnosis, Indi-
genous identification (reference group = non-Indigenous),
sex (reference group =male), rurality (regional; remote;
reference group =metropolitan), area-based deprivation
quintile (reference group =Q1), and broad cancer site
groupings (18 categories, as listed above). The adjusted
ratios from these models, comparing the differences in
average expenditure or frequency of use of each BTOS
based on Indigenous identification were calculated.
Finally, a counterfactual analysis was undertaken to
compare the actual frequency of occasions of service
associated with each BTOS for Indigenous patients that
would need to be supplied in a counterfactual scenario
where Indigenous patients had the same frequency of
services as their non-Indigenous counterparts. That is,
we calculated how many services Indigenous patients
would have had if they had the same level of services
use as non-Indigenous patients, after adjusting for age at
diagnosis, sex (reference group =male), rurality
(regional; remote; reference group =metropolitan),
area-based deprivation quintile (reference group =Q1),
and broad cancer site groupings (18 categories, as listed
above). We then estimated the counterfactual patient
expenditure associated with each BTOS based upon the
estimated counterfactual number of services that would
have been accessed and the actual average patient
co-payment per BTOS for Indigenous patients.
Weighting to the Australian population
As described previously [26], we weighted the adminis-
trative data to provide results that are representative of
the Australian population using the programmed SAS
macro, GREGWT. The benchmark used for this study
was the 2012 Australian cancer incidence rates by age
and sex [31] .
All analysis was undertaken using SAS V9.4 (SAS
Institute, Inc., Cary, NC, USA). Throughout the paper,
weighted data is presented unless otherwise stated. All
costs are reported in 2016–17 Australian dollars (AUD),
which were adjusted with the Reserve Bank of Australia
inflation calculator [32].
Human Research Ethics approval was obtained from
the Townsville Hospital and Health Service Human
Research Ethics Committee (HREC) (HREC/16/
QTHS/11), Australian Institute of Health and
Welfare (EO2017/1/343) and James Cook University
HREC (H6678). Permission to waive individual con-
sent was approved from Queensland Health under
the Public Health Act 2005. No identifiable informa-
tion was provided to the authors.
Results
A total of 25,560 individuals were diagnosed with cancer
in Queensland, Australia between July 2011 and June
2012. Once weighted, this represented 123,949
Australians (2% Indigenous and 98% non-Indigenous
Australians, not age-standardised). Table 2 reports the
descriptive demographic statistics of the people with
cancer in CancerCostMOD at diagnosis. Compared to
non-Indigenous people with cancer, a higher proportion
of Indigenous people with cancer were female, lived in
remote areas, and were in area-based deprivation
quintiles 1 and 2. Approximately one-third of all partici-
pants diagnosed with cancer had died within 36months
of diagnosis.
The total amount charged for services covered by the
MBS in the 36months following diagnosis was
$18,899,737 for Indigenous patients and $1,876,091,278
for non-Indigenous patients, of this 3.5% was made up
of co-payments for Indigenous patients and 7.9% was
made up of co-payments for non-Indigenous patients.
For prescriptions covered by the PBS, $16,144,895 was
charged for Indigenous patients, with 4.6% being made
up of co-payments, and $1,240,764,814 was charged for
non-Indigenous patients, with 5.7% being made up of
co-payments.
Table 2 Descriptive demographics, new cancer diagnoses





N 429 (1.7) 25,124 (98.3)
N (weighted) 2100 121,900
Died within 36 months
of diagnosis (N, %)*
720 (34.4) 39,400 (32.3)
Female (N, %)** 1050 (49) 54,000 (44)
Mean age at diagnosis (SD)** 57.4 (15.4) 65.9 (15.2)
Rurality¥**
Metropolitan (N, %) 600 (27.5) 57,900 (47.8)
Regional (N, %) 800 (38.1) 53,700 (44.3)
Remote (N, %) 750 (34.4) 9600 (7.9)
Area-based deprivation measure¥**
1st quintile – most deprived
(N, %)
600 (27) 10,750 (8.9)
2nd quintile (N, %) 150 (6.5) 5600 (4.6)
3rd quintile (N, %) 550 (24.5) 19,400 (16)
4th quintile (N, %) 600 (27) 55,500 (45.8)
5th quintile – least deprived
(N, %)
350 (15) 30,000 (24.7)
¥Those with missing postcode data at diagnosis were excluded (n = 151). **p
sig at <.01. *p sig at <.05
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Both Indigenous and non-Indigenous people with
cancer had higher expenditure on MBS and PBS
co-payments in the twelve months immediately
following diagnosis, than in the 13–24 and 25–36
months following diagnosis (Table 3). In the first 12
months post-diagnosis, the mean expenditure for non-
Indigenous people with cancer was approximately
$1074, which was more than double that of Indigen-
ous people with cancer ($401). While expenditure was
reduced in the 13–24 and 25–36 month periods for
both Indigenous and non-Indigenous people with
cancer, the large difference in expenditure between
Indigenous and non-Indigenous people remained con-
sistent during these periods.
The abbreviated output of the parameter estimates
produced from the stepwise generalised linear model
of patient expenditure for MBS and PBS combined
in the first thirty-six months following diagnosis are
shown in Table 4 (broad cancer type is not shown,
but is included in the model). Regardless of the
other demographic and social characteristics being
adjusted for, identifying as Indigenous remained a
significant predictor of patient expenditure at each
stage of the model. The co-efficient values suggest
that Indigenous people with cancer spent signifi-
cantly less on direct expenditure than their
non-Indigenous counterparts. In the final model,
those in area-based deprivation quintiles four and
five paid significantly more than those in quintile
one (the most disadvantaged quintile), while age at
diagnosis was also a significant predictor.
The average frequency of use for each BTOS service
for Indigenous and non-Indigenous individuals in this
dataset is shown in Table 5 along with the adjusted ratio
in number of services utilised. There was no significant
difference in the number of GP attendances based on
whether people with cancer identified as Indigenous,
however Indigenous people with cancer had 38% more
enhanced primary care visits, 54% more services with a
practice nurse, and 45% more other non-referred pri-
mary care services than non-Indigenous people with
cancer. In contrast, Indigenous people with cancer had
49% fewer specialist attendances than non-Indigenous
people with cancer. Indigenous people with cancer also
had 22% fewer pathology collection services, 32% fewer
pathology tests, and 25% fewer diagnostic imaging
services.
The expenditure associated with each BTOS in the
three years following diagnosis for Indigenous and
non-Indigenous people with cancer is shown in Table 6,
along with the adjusted cost ratio of expenditure for
each BTOS. This suggests that Indigenous patients
Table 3 Average annual patient co-payments (MBS and PBS combined) by Indigenous and non-Indigenous people
Time since
diagnosis
Indigenous Cancer Patients Non-Indigenous Cancer Patients
N Mean (SD) Median (IQR) Range N Mean (SD) Median (IQR) Range
0 to 12 months 1660 401 (817) 177 (425) 0–8568 97,200 1074 (1986) 450 (831) 0–81,814
13 to 24months 1480 200 (455) 67 (221) 0–6180 88,200 484 (876) 289 (404) 0–25,731
25 to 36months 1380 181 (421) 61 (226) 0–6046 83,100 441 (825) 269 (382) 0–32,691
Note: data is limited to those who survived each respective 12-month period
Table 4 Parameter estimates of independent variables in stepwise generalised linear regression model of annual patient co-
payment1,2
Variable Model 1: Sex, age and Indigenous
identification only
Model 2: Sex, age, Indigenous
identification + Rurality
Model 3: Sex, age, Indigenous
identification + Rurality + Disadvantage
Co-efficient SE p-value Co-efficient SE p-value Co-efficient SE p-value
Intercept 3.98 0.05 <.0001 4.05 0.05 <.0001 3.81 0.06 <.0001
Female −0.03 0.02 0.18 −0.03 0.02 0.13 −0.04 0.02 0.52
Age at diagnosis 0.007 0.001 <.0001 0.007 0.001 <.0001 0.01 0.001 <.0001
Indigenous identification −1.03 0.07 <.0001 −1.01 0.07 <.0001 −0.98 0.07 <.0001
Regional Area −0.15 0.02 <.0001 −0.04 0.02 0.11
Remote Area −0.16 0.03 <.0001 −0.01 0.04 0.83
Area-based deprivation Quintile 2 −0.04 0.05 0.39
Area-based deprivation Quintile 3 0.01 0.04 0.71
Area-based deprivation Quintile 4 0.19 0.04 <.0001
Area-based deprivation Quintile 5 0.30 0.05 <.0001
1MBS and PBS patient co-payments combined
2Abbreviated output, all models adjusted for cancer type
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spend significantly less on the majority of health services
than non-Indigenous patients. Despite Table 5 showing
Indigenous people with cancer access more or similar
numbers of non-referred services, Indigenous people
with cancer spent 58% less on GP services than
non-Indigenous people with cancer, 99.1% less on
enhanced primary care services, and 50% less on services
in the ‘other’ category.
Table 6 shows that Indigenous people with cancer also
had lower expenditure in total on these services. For ex-
ample, non-Indigenous people with cancer spent an
average of $978 on specialist patient co-payments in the
three years post diagnosis, whereas Indigenous people
with cancer spent an average of $260 on co-payments
for this type of service. After adjusting for age, sex, type
of cancer, rurality and area-based deprivation, Indigenous
people with cancer spent 75% less on specialist ser-
vices, 79% less for pathology tests, 74% less for diag-
nostic imaging and 61% less for operations. Overall
Indigenous people with cancer spent 75% less on all
services in the three years following their diagnosis
than non-Indigenous people with cancer.
Table 7 shows the actual number of BTOS services
accessed by Indigenous Australians, and the counterfactual
number of BTOS services that would be accessed if Indi-
genous Australians had utilised services at the same rate as
their non-Indigenous counterparts. For all BTOS services
combined, Indigenous Australians accessed an average of
236 services, but if Indigenous Australians had the same
rate of service use as their non-Indigenous counterparts,
the estimated number of services would increase to an
average of 309 services per person, resulting in an estimated
expenditure on co-payments of $3242.50. The actual
average expenditure (shown in Table 6) on all BTOS ser-
vices combined was $1191 for Indigenous people and
$4639 for non-Indigenous people.
Discussion
Ensuring equitable access lies at the core of universal health
care [33]. A significant part of this is ensuring that out of
pocket costs associated with accessing health care do not
cause financial distress, and as such do not affect individual
demand for, and access to health care services. The initial
results of this study indicated that Indigenous people with
Table 5 Average number and adjusted ratio of Medicare services by Indigenous status
BTOS name BTOS
code











Non-referred attendances – GP/VRGP 101 29 (25.8) 33.5 (26.8) 1.04
Non-referred attendances – enhanced primary care 102 6.2 (6.4) 5.3 (5.1) 1.38***
Non-referred attendances – other 103 5.4 (7.9) 4.4 (7.7) 1.45***
Non-referred attendances – practice nurse items 110 4.5 (6.8) 3.4 (4.4) 1.54***
Other allied health 150 10 (12.5) 10.2 (10.6) 1.07
Specialist attendances 200 14 (19.5) 28.6 (41.8) 0.51***
Anaesthetics 400 2.9 (2.3) 4.5 (4.5) 0.62***
Pathology collection items 501 32.2 (37.1) 46.2 (50.2) 0.78***
Pathology tests 502 38.7 (45.5) 61.3 (85.3) 0.68***
Diagnostic imaging 600 10.7 (9.9) 14.3 (11.9) 0.75***
Operations 700 6.1 (8.9) 9.2 (10.7) 0.71***
Assistance at operations 800 1.5 (0.9) 1.6 (1.1) 0.90
Optometry 900 2.4 (2.2 2.7 (2.5) 0.97
Other MBS Services 1000 37.2 (20.8) 39 (25.3) 0.93
Radiotherapy and therapeutic nuclear medicine 1100 34.9 (36.8) 44 (50.4) 1.02
All BTOS combined 177.3 (149.4) 248.5 (234) 0.80***
#Adjusted for age at diagnosis, Indigenous identification, sex, rurality, area-based deprivation quintile, and broad cancer site groupings
*significant at 0.05 level
**significant at 0.01 level
***significant at 0.001 level
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Table 6 Average expenditure and adjusted cost ratio of Medicare service types by Indigenous status
BTOS name BTOS
code




Non-referred attendances – GP/VRGP 101 73.4 (197) 162.6 (286) 0.42***
Non-referred attendances – enhanced primary care 102 0.05 (0.9) 2 (19.2) 0.009***
Non-referred attendances – other 103 22.8 (126.9) 46.9 (120.8) 0.50*
Non-referred attendances – practice nurse items 110 0.09 (1.1) 0.2 (2) 0.11
Other allied health 150 19.9 (93.9) 58.9 (183.8) 0.33**
Specialist attendances 200 260.3 (670.6) 978.3 (1650.2) 0.25***
Anaesthetics 400 580.9 (658.6) 1005.5 (1097.5) 0.54***
Pathology collection items 501 10.8 (48.1) 42.1 (128.2) 0.23***
Pathology tests 502 109.5 (440.5) 481.1 (1215.2) 0.21***
Diagnostic imaging 600 112.9 (329) 400.4 (768.6) 0.26***
Operations 700 671.3 (1463.7) 1797.9 (2510.7) 0.39***
Assistance at operations 800 366.8 (303.3) 392.1 (345.1) 0.83
Optometry 900 0.6 (4.9) 0.9 (5.7) 2.24
Other MBS Services 1000 159.4 (702.7) 682.7 (1487.2) 0.14***
Radiotherapy and therapeutic nuclear medicine 1100 85.8 (495.3) 375.8 (1233.9) 0.26***
All BTOS combined 1191 (3099) 4639 (6891) 0.25***
#Adjusted for age at diagnosis, sex, rurality, area-based deprivation quintile, and broad cancer site groupings
*significant at 0.05 level
**significant at 0.01 level
***significant at 0.001 level













if access was equal
Non-referred attendances – GP/VRGP 101 29 $73 33 $83.5
Non-referred attendances – enhanced primary care 102 6 $0.05 4 $0.03
Non-referred attendances – other 103 5 $23 4 $17
Non-referred attendances – practice nurse items 110 4 $0.09 3 $0.06
Other allied health 150 10 $20 9 $17.9
Specialist attendances 200 14 $260 30 $561.8
Anaesthetics 400 3 $581 4 $815.3
Pathology collection items 501 32 $11 47 $15.7
Pathology tests 502 39 $110 67 $189.5
Diagnostic imaging 600 11 $113 16 $168.7
Operations 700 6 $671 8 $877.5
Assistance at operations 800 2 $367 1 $241.3
Optometry 900 2 $0.6 2 $0.5
Other MBS Services 1000 37 $159 39 $167.2
Radiotherapy and therapeutic nuclear medicine 1100 35 $86 42 $103.2
ALL BTOS combined 236 $1191 309 $3242.5
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cancer in Australia pay significantly less on co-payments
for services covered under Medicare than non-Indigenous
people with cancer in the first three years after diagnosis.
However, this lower amount of expenditure was largely
driven by differences in patterns of service access between
the two groups, as well as lower co-payments for services
for Indigenous people with cancer.
Our results have shown that overall, Indigenous people
with cancer are accessing fewer services covered by
Medicare. This includes fewer pathology tests and diag-
nostic imaging services, as well as specialists, and radio-
therapy and therapeutic nuclear medicine services. It
may be that some Indigenous people with cancer are
accessing some specialist and radiotherapy services in
outpatient clinics at public hospitals. While many of
these services are billed through Medicare, in which case
they would be included in the results of this study, it is
also possible for such services to be funded by state and
territory health budgets and so would not be captured in
our data [34]. Indigenous people with cancer do access
more primary care services, such as services provided by
General Practitioners, than non-Indigenous people with
cancer. It is important to note that Indigenous people
with cancer are likely to have more co-morbidities [4],
which may explain this, at least in part.
In order to account for these differences in access pat-
terns, we modelled a counterfactual scenario whereby In-
digenous people with cancer had the same rate of access
to services covered under Medicare as non-Indigenous
people with cancer with otherwise the same demographic
and clinical characteristics. Results from this modelling in-
dicated that Indigenous people with cancer would incur
much higher (compared to their actual expenditure) out
of pocket expenditure for co-payments, an increase from
$1191 to $3243 over the three years following diagnosis.
The latter figure is still less than the $4639 paid by
non-Indigenous people with cancer, reflecting the lower
co-payment amounts for individual occasions of services
paid by Indigenous people with cancer.
These findings indicate that when Indigenous people
do access services, that Australia’s universal health care
policies, such as the Extended Medicare Safety Net and
Closing the Gap (CTG) Closing the Gap (CTG) PBS
Co-payment Programme, are supporting equity. Those
with greater need – Indigenous people with cancer have
known poorer survival outcomes – are receiving a
greater amount of financial re-imbursement. However,
the findings suggest substantial inequity in terms of
access to services – with Indigenous people with cancer
accessing far fewer services. These findings have import-
ant policy implications, with universal healthcare being
listed as one of the Sustainable Development Goals
(SDG) [35], which have been adopted by 150 world
governments including Australia. Australia’s ranking on
the SDG Index has declined between 2016 and 2018
from 26th to 37th [36], highlighting the need for im-
provement in all domains, including health. Yet de-
veloped countries, with long-established universal
health care systems, such as Australia, are having
the sustainability of their system questioned domes-
tically, particularly in light of tighter fiscal policy
environments following the Global Financial Crisis
[37]. Furthermore, within Australia, significant atten-
tion has been given to the actual performance of
Australia’s universal healthcare system [19, 38, 39].
Differences in access to services based upon socio-
economic status or location have been previously
documented [40, 41]. Our findings have shown that this
pattern is also true for Indigenous people with cancer.
This analysis does have a number of limitations that
need to be considered. Primarily the costs were limited to
co-payments for services listed under the MBS and pre-
scriptions for pharmaceuticals listed on the PBS. Payment
for services not covered under these schemes have not
been included. Furthermore, indirect cost associated with
travel and accommodation, childcare, lost wages from em-
ployment, and intangible costs such as time away from
family are also not included and as such we underestimate
the full costs to people with cancer. We were also unable
to identify any private health insurance rebates that may
have been paid for MBS services delivered in private hos-
pitals. As there is overlap between Indigenous status, rur-
ality and socioeconomic disadvantage within Australia,
the unique contribution that each factor played in predict-
ing cancer costs was not fully explored using the analysis
in this paper. Finally, the analysis was unable to adjust for
co-morbidities, which may have been higher in Indigenous
people with cancer; or for educational level.
Conclusion
While this study did find that Indigenous people with
cancer do pay less out of pocket for co-payments
associated with accessing care, it also highlighted deep
inequalities in terms of access to healthcare services pro-
vided under Medicare. These inequalities in access with
regards to equity in out of pocket payments between In-
digenous and non-Indigenous people with cancer, must
also be considered within in the context of the other
deep structural inequities that inhibit Indigenous peo-
ple’s access to care through impacting clinician or
patient-side decision-making. This study has highlighted
the challenges of assessing out of pocket expenditure.
While it appears that Indigenous people with cancer do
pay less when they do access services, overall they access
far fewer services than non-Indigenous people with can-
cer. It appears that this lower access may be having a
negative impact given the well-documented disparities in
cancer outcomes for Indigenous people with cancer.
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Endnotes
1However, hospital prescriptions are excluded from the
CTG PBS Co-Payment Programme.
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